Trial Profile
Phase II Study of Bortezomib Consolidation After High Dose Therapy and Autologous Stem Cell Transplantation for Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jul 2020
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 16 Apr 2019 Status changed from active, no longer recruiting to completed.
- 17 May 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
- 02 Dec 2014 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.